Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The FDA has approved new indications for Gilead’s Harvoni: to treat hepatitis C in those with genotypes 4, 5 and 6 of the virus and in...
Gilead has applied to the FDA for approval of the combo tablet of Sovaldi and velpatasvir to treat those with genotypes 1 through 6 of hep C
The FDA as given priority review status to BMS’s applications for new indication approvals for the hep C drug virus Daklinza.
It is not immediately available to your local pharmacy.
The FDA has approved BMS’s Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.
So far, the Harvoni combo pill had only been approved for use in the United States, the European Union and Canada.
The European Commission has approved Gilead Sciences’ hepatitis C virus (HCV) treatment Harvoni (ledipasvir/sofosbuvir).
The FDA has approved Gilead Sciences’ hotly anticipated new hepatitis C therapy Harvoni (ledipasvir/sofosbuvir).
The European Commission has approved Bristol-Myers Squibbâ€™s Daklinza (daclatasvir) to treat genotypes 1 through 4 of hepatitis C virus.
The FDA has approved Sovaldi (sofosbuvir), a once-daily oral nucleotide analog polymerase inhibitor to treat people with hepatitis C.
The FDA has approved Olysio (simeprevir) to treat those with genotype 1 of hepatitis C who have compensated liver disease, including...
Princeton, New Jersey-based Pharmasset is putting its lead experimental hepatitis C nucleotide inhibitor to the test in three late-stage...
The Antiviral Drugs Advisory Committee (ADAC) of the U.S. Food and Drug Administration voted 18 to 0 to recommend approval of telaprevir...
Merck announced Wednesday, April 27, that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration unanimously...
Two experimental hepatitis C virus protease inhibitors are scheduled to undergo approval review by the U.S. Food and Drug Administration’s..
Vertex Pharmaceuticals announced on January 20 that the U.S. Food and Drug Administration (FDA) has agreed to expedite its approval review of...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.